Myasthenia gravis is an chronic autoimmune disease that leads to muscle weakness. A clinical trial made over a five-year period by the Myasthenia Unit of the Vall d'Hebron university hospital has just demonstrated the benefits of including tacrolimus in the treatment of this disease.